Scholl Medical Receives EU Processing License (Aphria)


Schroll Medical ApS receives as one of the first producers a license for cultivation and medical cannabis processing.

Schroll Medical ApS, as the second company in Denmark, has just received a permit for cultivation and medical cannabis processing under the trial scheme. This means that Danish patients are now one steps closer to being able to buy Danish quality products grown without the use of pesticides within medical cannabis.

The permit requires an EU GMP certification, which is issued by the Danish Medicines Agency. The requirements for this are defined in drug standards, which sets extremely extensive requirements for both facilities, established quality systems as well as staff. It has been a very challenging task to become certified.

“It is therefore with great satisfaction that we have received this approval and we look forward to fighting moving forward with the next challenges up to getting the first product approved for the patients ”says CEO Carsten Garbo Schroll.

However, the way forward for the first products to be sold to Danish patients remains a minimum of 4 months, since there is both production time and process time for product approval at the Danish Medicines Agency.

Expectations at Schroll Medical ApS are high. The customer interest before the first sale is great, and on them markets where medical cannabis is introduced, including Canada, the United States and Israel, have the results of many patient groups have been incredibly positive. In connection with this, Carsten Garbo Schroll notes: “We have in Denmark has been favored by forward-looking politicians who have opened up the experimental scheme, as one of the first countries in the EU. We are at the forefront of the wave, but many countries are right on our heels, so a success depends on the persistence of both politicians and producers.”

About Schroll Medical ApS

Schroll Medical ApS is currently. the only manufacturer of medical cannabis that is both Danish-led and Danish owned and licensed for the cultivation and sale of medical cannabis.
Schroll Medical ApS has access to extensive experience with its parent company Schroll Management ApS plant breeding as well as the establishment of efficient plant production. The goal is that pharmaceutical production can use this knowledge to develop the most effective varieties and products in collaboration with doctors and universities in Denmark and the EU.

Subscribe to Money News Alerts

This article by Money News National is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Money News National has no position in the stocks mentioned. Thank you for reading.


This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.


Please enter your comment!
Please enter your name here